News Archives - Page 215 of 721

WednesdayDec 14, 2022 12:00 pm

Veloce Energy Pitched their Innovative EV Charging Infrastructure Platform at the 5th Annual Sustainability Private Capital Event

Veloce Energy participated in the 5th Annual Sustainability Private Capital Event on December 7-8, 2022 presented jointly by Sustain SoCal and Roth Capital Partners. Venture capitalists and investors from private equity, family offices, endowments, foundations and angels attended the event. Due to factors like high utility connection costs, high utility demand charges, and costly antiquated construction methods, EV charging stations are often un-profitable and take far too long to be deployed. Veloce Energy’s FastGrid software and hardware platform helps eliminate these barriers through its: Modular and scalable approach Integrated architecture Installation techniques Integrated resilience By incorporating the above dynamics, Veloce…

WednesdayDec 14, 2022 11:15 am

Energy Access and Climate Change Trends Converge to Drive Correlate Infrastructure Partners Inc. (CIPI) Solutions for Distributed Energy Resources

Industries and governments worldwide have been battered in recent years by the fallout from the COVID pandemic and the war in Ukraine as it pertains to energy access and climate change Global industries are pursuing distributed energy resource (“DER”) micro-networks for providing a more localized power infrastructure reliant on carbon-free renewable energy North America-based Correlate Infrastructure Partners Inc. is a clean energy solutions innovator that works with clients on reducing their carbon footprint through smart energy utilization decisions and project financing Experienced leadership, such as the fiscal management provided by CFO Channing Chen, who was recently featured in a company…

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials…

WednesdayDec 14, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Remains Committed to Improving Road Safety Through Development of Lidar Solutions for Assisted and Autonomous Driving

Nearly all automotive OEMs have plans to include lidar sensors within their assisted and automated driving platforms Gaining public trust in the ability of vehicles to operate safely while providing automated driving features will be a key milestone for widespread adoption L2+/L3 ADAS is likely to be an enabler as it helps ease the public with broader hands-free functions while maintaining the ability to take over as needed Cepton’s lidar sensors are uniquely positioned to benefit from these core industry growth trends and the Company remains committed to delivering superior driving experiences with added safety and convenience Automotive OEMs have…

WednesdayDec 14, 2022 9:00 am

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Offers Solutions for Smart Businesses to Keep Making Cybersecurity a Priority

Cost-cutting becomes a priority for businesses looking to remain strong during record inflation “It’s always a question of what to prioritize and which costs to minimize while preserving the quality of your product,” states a Forbes article Cerberus ensures that companies not only stay more secure but also build a culture of cybersecurity In a fragile economy with a possible recession looming on the horizon, savvy companies are taking a close look at ways to tighten their belts. As they do so, a recent Forbes article cautions wise business leaders to keep cybersecurity in the forefront (https://ibn.fm/ui99g), a strategy that…

TuesdayDec 13, 2022 12:00 pm

Coyuchi Inc. Offers Gold Standard Luxury Home Goods to Satisfy Growing Market of Sustainability-Conscious Consumers

66% of US consumers (80% of consumers aged 18-34) are willing to pay more for products made with sustainability in mind The luxury home décor market is expected to reach $207 billion by 2027, growing from $118 billion in 2020 at a CAGR of 5.14% Coyuchi guarantees the highest environmental and ethical standards through its certifications - The Global Organic Textile Standard (“GOTS”), Fair Trade Certified, and MADE SAFE(R) Coyuchi is built upon four foundational pillars – protecting the environment, innovating circular design, living sustainably, and enriching the community – with over 1400 SKUs made from 100% organic cotton The…

TuesdayDec 13, 2022 11:15 am

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) Unveils Commercial Prototype of its ZVS Inverter Technology

Hillcrest Energy Technologies recently unveiled a commercial prototype of its 800-volt, 250-kilowatt Zero Voltage Switching (“ZVS”) traction inverter The production of a commercial prototype comes only months after the company had published white papers, extolling the potential of their revolutionary technology The inverter will be developed and integrated alongside Hillcrest’s partners, Hercules Electric Mobility as well as a separate Tier 1 automotive supplier The company envisions its inverter technology being deployed with batteries, electric motors, generators, fuel cells and any other power source requiring power conversion Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology company focused on developing…

TuesdayDec 13, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks) The company has also started investigating DehydraTECH-CBD as a…

TuesdayDec 13, 2022 9:45 am

SideChannel Inc. (SDCH) Brings On Principal Consultant to Provide Top-Tier Security Guidance at Manageable Cost

SideChannel is a company making cybersecurity accessible and simple, especially for small and mid-sized businesses (“SMBs”) The company provides cybersecurity services in the form of virtual CISOs (“vCISOs”), engineering services that enable the vCISOs to provide operational day-to-day security and privacy to clients, and proprietary security software called Enclave SideChannel’s differentiator from its competition is its team of experts, and recently the company hired IT and cybersecurity veteran Sean Higgins as Principal Consultant In this role, Sean will help client companies’ CISOs and senior management evaluate and have greater levels of confidence in their security programs SideChannel (OTCQB: SDCH), a…

TuesdayDec 13, 2022 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025 A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid…

Site Search

Company Search

Category: News